Amphastar Pharmaceuticals Inc
Закрыт
СекторЗдравоохранение
19.97 -2.2
Обзор
Изменение цены акций
24 ч
Мин.
19.97
Макс.
20.24
Доход | -18M 6.4M |
|---|---|
Продажи | -12M 171M |
P/E Средняя по отрасли | 11.681 49.052 |
Прибыль на акцию | 0.42 |
Рентабельность продаж | 3.751 |
Сотрудники | 1,976 |
EBITDA | -25M 14M |
Рекомендации | Нейтрально |
|---|---|
Прогноз на 12 месяцев | +6.52% upside |
Следующий отчет о доходах | 6 авг. 2026 г. |
|---|
Рыночная капитализация | -158M 855M |
|---|---|
Предыдущая цена открытия | 22.17 |
Предыдущая цена закрытия | 19.97 |
Новостные настроения
By Acuity
21%
79%
42 / 342 Рейтинг в Healthcare
Amphastar Pharmaceuticals Inc График
Прошлые результаты не являются надежным индикатором будущих результатов.
О компании Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.